Is a Soliris patent review that big a threat to Alexion? Analysts are split

4th September 2019 Uncategorised 0

Things haven’t gone Alexion’s way lately: After investors cheered the possibility of an Amgen merger, the hoped-for partner advanced its Soliris patent challenge. The possibility of losing their bestseller’s protection has spooked investors, but analysts wonder—is it that big of a deal?

More: Is a Soliris patent review that big a threat to Alexion? Analysts are split
Source: fierce